etapidi can help people with ESCC respond to treatment and live longer
etapidi + chemotherapy was studied in a clinical trial of 649 people who had ESCC. Of these, 481 patients had a PD-L1 score ≥1%, like you. Those included in the trial:
- Had cancer that had spread
- Could not have their cancer removed with surgery
- Had not received treatment for this stage of their cancer
Survival Advantage with ETAPIDI + Chemotherapy
More people who received etapidi + chemotherapy (21% of patients) were still alive at 3 years than those who received placebo + chemotherapy (14% of patients).
Tumor Response: Shrinkage Rate
More people who received etapidi + chemotherapy (21% of patients) were still alive at 3 years than those who received placebo + chemotherapy (14% of patients).
Placebo is an inactive treatment used to compare with active treatments.
Response means that the tumor has shrunk or disappeared completely.
ESCC, esophageal squamous cell carcinoma; PD-L1, programmed death ligand 1.